Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
2007

Comparing HER2 Testing Kits for Breast Cancer

Sample size: 55 publication Evidence: high

Author Information

Author(s): Cayre Anne, Mishellany Florence, Lagarde Nicole, Penault-Llorca Frédérique

Primary Institution: Département de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France

Hypothesis

The study aims to compare the accuracy of four commercially available HER2 testing kits.

Conclusion

The INFORM kit, with an appropriate cutoff, is comparable to dual-probe FISH kits for evaluating HER2 status.

Supporting Evidence

  • HER2 amplification was observed in 31% of tumors by PathVysion compared with 33% with pharmDx.
  • Agreement was excellent between PathVysion and pharmDx (100%).
  • Agreement with INFORM improved to 98% with a cutoff of at least six signals per nucleus.
  • CISH was validated as an appropriate assay for HER2 scoring that is easy to interpret.

Takeaway

This study looked at different kits to see which one does the best job at checking if breast cancer cells have a special marker called HER2. They found that one kit works just as well as the best one.

Methodology

The study compared four HER2 testing kits using tumor samples from patients and evaluated their accuracy against the FDA-approved PathVysion kit.

Limitations

The study may not account for all variables affecting HER2 testing accuracy, and results may vary with different populations.

Participant Demographics

Patients with invasive breast carcinoma, specifically those with HER2 IHC 2+ cases.

Statistical Information

P-Value

p=0.00031

Digital Object Identifier (DOI)

10.1186/bcr1770

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication